Restylane Skinboosters Vital Light Lidocaine 1x1ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Restylane Skinboosters Vital Light with lidocaine is the light variant of the Galderma Skinbooster: 12 mg/ml of NASHA® stabilised hyaluronic acid compared with the 20 mg/ml of Vital. It is deposited in the mid dermis and is intended for thin skin and for subtle results, with a shorter three-session protocol and a lower dose limit than Vital.
- Stabilised HA 12 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Contents 1 syringe × 1.0 ml
- Needle 29G TW
- Protocol 3 sessions / 2–4 weeks
Composition and technology
- Stabilised hyaluronic acid: 12 mg/ml, of non-animal origin. This is the differentiating element compared with Vital (20 mg/ml).
- Lidocaine hydrochloride: 3 mg/ml, the same concentration as in Vital.
- NASHA® technology: small-particle stabilised hyaluronic acid. The lower concentration results in a more fluid gel, which distributes more readily in the mid dermis and in skin of lesser thickness.
- Purpose: skin hydration and elasticity. It is not a volumising product and is not formulated to correct folds.
Position within the range: NASHA and OBT
The entire Restylane range is built on two distinct gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that retain the long hyaluronic acid chains with minimal cross-linking. High resistance and very low strain tolerance: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, marketed as XpresHAn Technology™ in the United States): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high strain tolerance: the gel follows the movement of the tissue, which is why it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, midface, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, with no volumising purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values are taken from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
Improvement of skin elasticity.
- Lower facial third and jawline
- Upper cervical region
These are the areas documented in the manufacturer's instructions for use. Use on the décolleté, dorsum of the hands or other areas falls outside the indication and is the responsibility of the practitioner who prescribes it.
Technique and treatment protocol
- Injection plane: mid dermis — more superficial than Vital, which is deposited in the deep dermis.
- Needle included: 29G thin wall (TW), disposable. Alternatively, a sterile 30G blunt cannula may be used, with the side port oriented downwards.
- Technique: microdeposits with slow injection and minimal pressure.
- Initial protocol: 3 sessions 2 to 4 weeks apart.
- Maintenance: one session every 4 to 6 months.
- Manufacturer's dose limits: maximum 3.5 ml per session and 17.5 ml per patient per year (Vital: 5 ml and 20 ml respectively).
Technical data
| Manufacturer | Q-Med AB (Galderma) — Uppsala, Sweden |
|---|---|
| Active substance | Stabilised hyaluronic acid 12 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml |
| Technology | NASHA® — small particle |
| Presentation | 1 glass syringe of 1.0 ml |
| Needle | 29G TW (alternative: 30G blunt cannula) |
| Treatment plane | Mid dermis |
| Protocol | 3 sessions every 2–4 weeks; maintenance every 4–6 months |
| Maximum dose | 3.5 ml per session · 17.5 ml per patient per year |
| Sterilisation | Moist heat (syringe contents) / ethylene oxide (needles) |
| Classification | CE-marked medical device (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight.
- Do not use after the expiry date stated on the pack.
- Single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 glass syringe of 1.0 ml with finger grip and plunger rod, disposable 29G TW needle, instructions for use and a traceability label for the patient record.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; coagulation disorders; history of keloid scarring; active skin inflammation or infection in the area to be treated.
Caution and individual assessment: anticoagulant or antiplatelet therapy (increased risk of haematoma and bleeding at the puncture site); autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection may cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbances, blindness or stroke. Aspiration before injecting and a low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (instructions for use Restylane® Skinboosters™ Vital Light Lidocaine, Q-Med AB / Galderma). This information sheet does not replace the instructions for use supplied with the product.